Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab in Chinese Subjects With Advanced Small Cell Lung Cancer (DeLLphi-307)
NCT06502977Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Aug 2024
- Primary completion
- Mar 2025
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Amgen. Primary endpoint: Objective Response Rate Based on Blinded Independent Central Review at 3.4 months. Started Aug 2024; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06502977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06502977.